Data from an Italian, multicenter clinical trial in 312 breast cancer patients with newly diagnosed bone metastases confirms the renal safety of zoledronic acid (Zometa®)

被引：0
|
作者：
Carten, G [1 ]
Bordonaro, R [1 ]
Colucci, G [1 ]
Lorusso, V [1 ]
Veronesi, A [1 ]
Marrè, MC [1 ]
Rondena, BR [1 ]
Vinaccia, V [1 ]
Amadori, D [1 ]
机构：
[1] AORN A Cardarelli, Naples, Italy
来源：
BONE | 2004年 / 34卷
关键词：
zoledronic acid; bone metastases; breast cancer; bisphosphonate;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S83 / S84
页数：2
相关论文
共 50 条
  • [1] Final efficacy and safety results of an Italian, multicenter clinical trial in 312 breast cancer patients with newly diagnosed bone metastases treated with zoledronic acid.
    Carteni, GG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 83S - 83S
  • [2] Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: A multicenter clinical trial
    Carteni, Giacomo
    Bordonaro, Roberto
    Giotta, Francesco
    Lorusso, Vito
    Scalone, Simona
    Vinaccia, Vincenza
    Rondena, Roberta
    Amadori, Dino
    [J]. ONCOLOGIST, 2006, 11 (07): : 841 - 848
  • [3] Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases
    Murat Dincer
    Kadri Altundag
    Hakan Harputluoglu
    Sercan Aksoy
    Mustafa Cengiz
    Ibrahim Gullu
    [J]. Medical Oncology, 2008, 25 : 356 - 359
  • [4] Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases
    Altundag, M. K.
    Dincer, M.
    Harputluoglu, H.
    Aksoy, S.
    Ozisik, Y.
    Guler, N.
    Tekuzman, G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases
    Dincer, Murat
    Altundag, Kadri
    Harputluoglu, Hakan
    Aksoy, Sercan
    Cengiz, Mustafa
    Gullu, Ibrahim
    [J]. MEDICAL ONCOLOGY, 2008, 25 (03) : 356 - 359
  • [6] Impairment of renal function in the breast cancer patients with bone metastases treated with zoledronic acid
    Ito, Tokiko
    Ono, Mayu
    Oba, Takaaki
    Hanamura, Toru
    Kanai, Toshiharu
    Maeno, Kazuma
    Hiraguri, Manabu
    Shingu, Kiyoshi
    Kaneko, Gengo
    Ito, Ken-ichi
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 103 - 103
  • [7] IMPAIRMENT OF RENAL FUNCTION IN THE BREAST CANCER PATIENTS WITH BONE METASTASES TREATED WITH ZOLEDRONIC ACID
    Ito, T.
    Shingu, K.
    Kaneko, G.
    Ito, K. -I.
    [J]. ANNALS OF ONCOLOGY, 2013, 24
  • [8] Phase III trial of oral ibandronate and intravenous zoledronic acid in breast cancer patients with bone metastases: comparative bone turnover marker and safety data
    不详
    [J]. EJC SUPPLEMENTS, 2006, 4 (02): : 164 - 165
  • [9] Long-term safety of zoledronic acid for the treatment of patients with breast cancer and bone metastases
    Lipton, A.
    Dewar, R.
    Conte, R.
    Zheng, M.
    [J]. EJC SUPPLEMENTS, 2004, 2 (03): : 142 - 142
  • [10] Osteonecrosis of the jaw/maxilla in breast cancer patients treated with zoledronic acid (Zometa®) for bone metastases:: Data on one-hundred and five consecutive women at a single institution
    Rosati, M.
    Cacciari, N.
    Bernardi, A.
    Quercia, S.
    Zamagni, C.
    Pizzigallo, A.
    Marchetti, C.
    Martoni, A.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : XI68 - XI69
12345